USA – Lyndra Therapeutics, a clinical-stage biopharmaceutical company focused on advancing long-acting oral drugs, has entered into a strategic collaboration with Thermo Fisher Scientific to support its research and manufacturing needs.
Under the partnership announced during the 2025 J.P. Morgan Healthcare Conference in San Francisco, Thermo Fisher will provide global clinical research and commercial-scale manufacturing services for Lyndra’s innovative therapies.
The collaboration will utilize Thermo Fisher’s advanced manufacturing facility in Cincinnati, Ohio, to support Lyndra’s commercial production.
Lyndra’s technology platform enables stable and sustained drug delivery for a week or longer using a single oral dose, a groundbreaking approach designed to transform medication adherence and patient care.
This partnership follows Lyndra’s recent phase 3 efficacy success for its long-acting risperidone candidate, LYN-005, for treating schizophrenia and schizoaffective disorder.
In January 2024, Lyndra reported that LYN-005, a novel weekly version of the daily schizophrenia medication Risperdal, demonstrated comparable efficacy to the daily formulation during an interim analysis.
The positive results prompted Lyndra to end the trial early, with plans to initiate a phase 3 safety trial for LYN-005 in the first half of 2025.
Dr. Richard Scranton, President of Global Product Development and Chief Medical Officer at Lyndra Therapeutics, emphasized the importance of the collaboration, stating, “Lyndra’s clinical research and manufacturing collaboration with Thermo Fisher is a critical step in our mission to transform how patients take medicine.
This partnership provides the capabilities and scale to bring long-acting oral therapies to broad markets while allowing Lyndra to focus on R&D for innovative solutions.”
The collaboration leverages Thermo Fisher’s Accelerator Drug Development services, which offer customizable manufacturing, clinical research, and supply chain solutions from preclinical stages through commercialization.
The company’s 360° Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services will streamline Lyndra’s clinical development and production processes.
Michael Shafer, Executive Vice President and President of Biopharma Services at Thermo Fisher, expressed enthusiasm for the partnership, saying, “Thermo Fisher is pleased to collaborate with Lyndra on its revolutionary drug delivery platform.
Leveraging our Accelerator Drug Development and comprehensive CDMO and CRO solutions exemplifies our commitment to simplifying the complex journey of clinical development and helping bring these groundbreaking therapies to patients.”
As part of the collaboration, Lyndra plans to use Thermo Fisher’s advanced pharmaceutical manufacturing capabilities to scale production of its LYNX drug delivery platform, further advancing its goal of delivering long-acting oral therapies to global markets.